Search results for "xina"

showing 10 items of 67 documents

Analysis of enniatins and beauvericin by LC-MS/MS in wheat-based products

2017

Due to the matrix complexity for wheat-based products, a comparative study of different rapid extraction procedures was performed for the extraction of enniatins (ENA, ENA1, ENB, ENB1) and beauvericin in flour, pasta, breakfast cereals, and biscuits. Three different approaches were studied during the extraction and purification steps (shaker, Ultra-Turrax, and QuEChERS) for each matrix. Liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) with electrospray source working in a positive mode was used. For the analysis of the five mycotoxins, the three methods were tested in terms of recovery, matrix effect, and sensibility, concluding that Ultra-Turrax extraction was the most …

Electrospraymethod validation ; productos elaborados con trigo ; LC-MS/MS ; Emerging mycotoxins ; Microtoxinas emergentes ; validación ; cereal-based productsGeneral Chemical Engineeringlcsh:TX341-641Tandem mass spectrometryQuechersIndustrial and Manufacturing EngineeringMatrix (chemical analysis)chemistry.chemical_compound0404 agricultural biotechnologyLc ms msLC-MS/MSMycotoxinChromatographylcsh:TP368-456Extraction (chemistry)method validation04 agricultural and veterinary sciencesGeneral Chemistry040401 food scienceBeauvericinlcsh:Food processing and manufacturechemistryEmerging mycotoxinslcsh:Nutrition. Foods and food supplyFood Sciencecereal-based products
researchProduct

Modelos de ataxia de Friedreich en Drosophila: identificación de candidatos terapéuticos y caracterización de un modelo portador de las repeticiones …

2018

La ataxia de Friedreich es una enfermedad neurodegenerativa hereditaria que constituye la ataxia autosómica recesiva más común a nivel mundial. La ataxia de la marcha es el síntoma más temprano, pudiéndose encontrar otros síntomas neurológicos como disartria, disfagia o neuropatías ópticas y auditivas, y síntomas no neurológicos como deformidades esqueléticas, diabetes y cardiomiopatía hipertrófica. La enfermedad está causada en la mayoría de los pacientes por la presencia en homocigosis de una expansión patológica de las repeticiones del triplete GAA situadas en el intrón 1 del gen FXN. Dicha mutación provoca la represión transcripcional del gen y la reducción de los niveles de la proteína…

FrataxinaUNESCO::CIENCIAS DE LA VIDA::GenéticaUNESCO::CIENCIAS DE LA VIDA::Biología molecular:CIENCIAS DE LA VIDA::Genética [UNESCO]UNESCO::CIENCIAS DE LA VIDA::Biología animal (Zoología) ::Genética animalAtaxiaDrosophila:CIENCIAS DE LA VIDA::Biología animal (Zoología) ::Genética animal [UNESCO]:CIENCIAS DE LA VIDA::Biología molecular [UNESCO]
researchProduct

Indicaciones de los inhibidores de PCSK9 en la práctica clínica. Recomendaciones de la Sociedad Española de Arteriosclerosis (SEA), 2019

2019

Resumen Un grupo de expertos convocado por la Sociedad Espanola de Arteriosclerosis (SEA) se ha encargado de actualizar el documento de la SEA sobre las indicaciones de los inhibidores de PCSK9 (iPCSK9) en la practica clinica publicadas en 2016. Esta actualizacion es necesaria porque en el periodo transcurrido hasta la actualidad se han publicado los resultados de los ensayos clinicos realizados a gran escala con iPCSK9 que demuestran que, ademas de su alta potencia para disminuir el colesterol aterogenico, disminuyen el riesgo de presentar episodios de enfermedad cardiovascular aterosclerotica en los pacientes con enfermedad tanto estable como reciente, y con un alto grado de seguridad. La…

Inhibidores de la proproteína convertasa subtilisina kexina 9ArteriosclerosisEnfermedad cardiovascularFamilial hypercholesterolemiaClinical indicationsLow density lipoprotein030204 cardiovascular system & hematologyArteriosclerosi03 medical and health sciencesLipoproteínas de baja densidad0302 clinical medicineIndicaciones clínicasTratamientoPharmacology (medical)030212 general & internal medicineConsensus documentHipercolesterolemia familiarNumber needed to treatCardiovascular diseaseDocumento de consensoTreatmentArterioesclerosiCholesterolProprotein convertase subtilisin kexin 9 inhibitorsCardiology and Cardiovascular MedicineColesterolNúmero necesario a tratar
researchProduct

Effects of long-acting bronchodilators in COPD patients according to COPD severity and ICS use

2013

SummaryBackgroundIndacaterol is a once-daily, long-acting β2-agonist bronchodilator that improves dyspnoea and health status in patients with moderate-to-severe COPD. While its bronchodilator effects have been shown to be maintained in different patient subgroups, effects on clinical outcomes in certain subgroups are not yet defined.MethodsPost-hoc analysis of pooled clinical study data to investigate efficacy and safety of indacaterol compared with placebo and other long-acting bronchodilators (formoterol, salmeterol, open-label tiotropium) in patient subgroups defined by COPD severity (GOLD stage II or III; n = 4082) and ICS use at baseline (no/yes; n = 4088). Efficacy outcomes were troug…

MaleCopd patientsVital CapacityQuinolonesSeverity of Illness IndexPulmonary Disease Chronic ObstructiveForced Expiratory VolumeFormoterol FumarateBronchodilatorFormoterolSalmeterolSalmeterol XinafoateRandomized Controlled Trials as TopicIndacaterolCOPDMiddle AgedBronchodilator AgentsTreatment OutcomeEthanolaminesAnesthesiaIndansDrug Therapy CombinationFemaleSalmeterolmedicine.drugAdultPulmonary and Respiratory Medicinemedicine.medical_specialtymedicine.drug_classScopolamine DerivativesPlaceboDrug Administration ScheduleInternal medicineAdministration InhalationmedicineHumansCOPDAlbuterolTiotropium BromideAdrenergic beta-2 Receptor AgonistsGlucocorticoidsAgedbusiness.industryTiotropiummedicine.diseaserespiratory tract diseasesDyspneaLong actingIndacaterolFormoterolbusinessRespiratory Medicine
researchProduct

Clinical and Biological Heterogeneity in Children with Moderate Asthma

2003

To evaluate the relationship between inflammatory markers and severity of asthma in children, the amount of interleukin-8 (IL-8) and granulocyte/macrophage colony-stimulating factor (GM-CSF) released by peripheral blood mononuclear cells, exhaled nitric oxide (FE NO) levels, p65 nuclear factor-kappaB subunit, and phosphorylated IkBalpha expression by peripheral blood mononuclear cells were assessed in six control subjects, 12 steroid-naives subjects with intermittent asthma, and 17 children with moderate asthma. To investigate their predictive value, biomarker levels were correlated with the number of exacerbations during a 18-month follow-up period. We found that GM-CSF release was higher …

MaleExacerbationAnti-Inflammatory AgentsCritical Care and Intensive Care MedicineSynaptotagminsMedicineChildSalmeterol XinafoateCalcium-Binding ProteinMembrane GlycoproteinsRespiratory diseaseNF-kappa Binflammatory markersBronchodilator AgentsAnti-Inflammatory AgentSynaptotagmin IBiomarker (medicine)FemaleMembrane GlycoproteinAndrostadienes; Anti-Inflammatory Agents; NF-kappa B; Leukocytes Mononuclear; Membrane Glycoproteins; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Synaptotagmins; Albuterol; Asthma; Child; Receptors Cell Surface; Nerve Tissue Proteins; Nitric Oxide; Synaptotagmin I; Calcium-Binding Proteins; Interleukin-8; Adolescent; Bronchodilator Agents; Male; Biological Markers; Femalemedicine.symptomHumanmedicine.drugPulmonary and Respiratory MedicineAdolescentNerve Tissue ProteinsReceptors Cell SurfaceInflammationNitric OxidePeripheral blood mononuclear cellFluticasone propionateHumansAlbuterolBronchodilator AgentAsthmaAndrostadienefluticasone propionatebusiness.industryCalcium-Binding ProteinsInterleukin-8Granulocyte-Macrophage Colony-Stimulating Factormedicine.diseaseSynaptotagminAsthmaAndrostadienesasthma; inflammatory markers; fluticasone propionateNerve Tissue ProteinBiological MarkerExhaled nitric oxideImmunologyLeukocytes MononuclearFluticasonebusinessBiomarkersAmerican Journal of Respiratory and Critical Care Medicine
researchProduct

Additive Effects of Salmeterol and Fluticasone or Theophylline in COPD

2000

ss(2)-Agonists and corticosteroids or theophylline can interact to produce beneficial effects on airway function in asthma, but this has not been established in COPD.Eighty patients with well-controlled COPD were randomized to receive 3 months of treatment in one of four treatment groups: (1) salmeterol, 50 microg bid; (2) salmeterol, 50 microg, plus fluticasone propionate, 250 microg bid; (3) salmeterol, 50 microg, plus fluticasone propionate, 500 microg bid; and (4) salmeterol, 50 microg, plus titrated theophylline bid. At each visit, a dose-response curve to inhaled salbutamol was constructed using a total cumulative dose of 800 microg.A gradual increase in FEV(1) was observed with each …

MalePulmonary and Respiratory Medicinemedicine.drug_classPharmacologyCritical Care and Intensive Care MedicineFluticasone propionateTheophyllineForced Expiratory VolumeBronchodilatorAdministration InhalationmedicineHumansAlbuterolTheophyllineLung Diseases ObstructiveGlucocorticoidsSalmeterol XinafoateAgedFluticasoneDose-Response Relationship Drugbusiness.industryDrug SynergismAdrenergic beta-AgonistsMiddle AgedMetered-dose inhalerBronchodilator AgentsAndrostadienesAnesthesiaSalbutamolFluticasoneCorticosteroidDrug Therapy CombinationFemaleSalmeterolCardiology and Cardiovascular Medicinebusinessmedicine.drugChest
researchProduct

Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: A 12-week study

2011

SummaryBackgroundIndacaterol is a novel, inhaled once-daily ultra-long-acting β2-agonist for the treatment of COPD.MethodsThis 12-week randomised, parallel-group study compared the efficacy of indacaterol 150 μg once-daily to salmeterol 50 μg twice-daily in patients with moderate-to-severe COPD. Assessments included FEV1 standardised area under curve (AUC) from 5 min to 11 h 45 min at Week 12 (primary endpoint), 24-h trough FEV1 (mean of 23 h 10 min and 23 h 45 min post-dose) at Week 12 (key secondary endpoint), FEV1 and FVC measured over 24-h, transition dyspnoea index (TDI) and rescue medication use.ResultsOf 1123 patients randomised 92.1% completed. Mean ± SD age was 62.8 ± 8.78 years, p…

MalePulmonary and Respiratory Medicinemedicine.drug_classbeta2-agonistQuinolonesDrug Administration Schedulelaw.inventionFEV1/FVC ratioPulmonary Disease Chronic ObstructiveRandomized controlled trialDouble-Blind MethodlawBronchodilatorForced Expiratory VolumeClinical endpointmedicineCOPDHumansAlbuterolSalmeterolSalmeterol XinafoateIndacaterolCOPDDose-Response Relationship Drugbusiness.industryrespiratory systemMiddle Agedmedicine.diseaserespiratory tract diseasesBronchodilator AgentsRespiratory Function TestsTreatment OutcomeAnesthesiaIndansIndacaterolFemaleSalmeterolOnce dailybusinessBronchodilatormedicine.drugRespiratory Medicine
researchProduct

Serious Asthma Events with Fluticasone plus Salmeterol versus Fluticasone Alone

2016

BACKGROUND The safe and appropriate use of long-acting beta-agonists (LABAs) for the treatment of asthma has been widely debated. In two large clinical trials, investigators found a potential risk of serious asthma-related events associated with LABAs. This study was designed to evaluate the risk of administering the LABA salmeterol in combination with an inhaled glucocorticoid, fluticasone propionate. METHODS In this multicenter, randomized, double-blind trial, adolescent and adult patients (age, ≥12 years) with persistent asthma were assigned to receive either fluticasone with salmeterol or fluticasone alone for 26 weeks. All the patients had a history of a severe asthma exacerbation in t…

Maleasthma ; serious events ; fluticasone ; salmeterol ; AUSTRIExacerbationIntention to Treat AnalysiINHALED CORTICOSTEROIDSSeverity of Illness Indexlaw.invention0302 clinical medicineRandomized controlled triallawimmune system diseasesÚs terapèuticBroncodilatadors030212 general & internal medicineChildFluticasoneRISKACTING BETA-AGONISTS; INHALED CORTICOSTEROIDS; RISK; EXACERBATIONS; METAANALYSIS; MORTALITY; SAFETY; DEATH; FDAMedicine (all)Hazard ratioDEATHGeneral MedicineBronchodilator agentsMiddle AgedFluticasone-Salmeterol Drug CombinationBronchodilator AgentsIntention to Treat AnalysisAnesthesiaSAFETYFemaleSalmeterolFDAmedicine.drugHumanAdultmedicine.medical_specialtyAdolescentSettore MED/10 - Malattie Dell'Apparato RespiratorioFluticasone propionate03 medical and health sciencesDouble-Blind MethodInternal medicineAdministration InhalationmedicineHumansMETAANALYSISAsmaBronchodilator AgentAsthmaAgedProportional Hazards ModelsFluticasone-Salmeterol Drug Combinationbusiness.industryMORTALITYACTING BETA-AGONISTSTherapeutic usemedicine.diseaseAsthmarespiratory tract diseasesEXACERBATIONS030228 respiratory systemFluticasone Propionate Salmeterol Xinafoate Drug CombinationProportional Hazards ModelFluticasonebusiness
researchProduct

Relacion de la persecucion, que padecieron los christianos, y cinco Religiosos del Orden de Predicadores en la Provincia de Fokien, Imperio de la Chi…

1750

Sig. A-K4, L2 Reclams. - Alguna capital grav. - Escut xil. dels dominicans a la p. 81

Màrtirs dominicans Xina Obres anteriors a 1800Dominicans Missions Xina Obres anteriors a 1800Persecucions religioses Xina Obres anteriors a 1800DIG-BHPere Màrtir Sanç i Jordá (1680- 1747) Obres anteriors a 1800
researchProduct

Relación del martirio de los VV. PP. el Ilmo. Sr. D. Fr. Francisco Serrano ..., Fr. Juan Alcober, Fray Joaquín Royo y Fray Francisco Diaz ..., pers…

1750

Sig. A-F4 Reclams. - Capital grav. i friso tip. en pàg. 1

Màrtirs dominicans Xina Obres anteriors a 1800Franciscans Missions Xina Obres anteriors a 1800Dominicans Missions Xina Obres anteriors a 1800Persecucions religioses Xina Obres anteriors a 1800Jesuïtes Missions Xina Obres anteriors a 1800
researchProduct